^
Association details:
Biomarker:CDKN2A deletion
Cancer:Diffuse Large B Cell Lymphoma
Drug Class:T-lymphocyte cell therapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

IMPACT OF TP53 AND RECURRENT SOMATIC MUTATIONS ON THE OUTCOMES OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T)

Published date:
05/12/2021
Excerpt:
This is a single center experience of R/R DLBCL patients treated with CAR-T...The 3-month progression rate was 2/7 (29%) for TP53mut and 6/8 (75%) for TP53wt with significantly higher PFS probability in TP53mut patients (p = 0.002). The 3-month progression rates for CDKN2A/B loss and wild-type were 5/5 (100%) and 3/10 (30%) respectively with lower PFS probability in patients with CDKN2A/B loss (p<0.001).